Literature DB >> 29554467

Contribution of Breast Cancer to Overall Mortality for US Women.

Ronald E Gangnon1,2,3, Natasha K Stout4, Oguzhan Alagoz2,3,5, John M Hampton2,3, Brian L Sprague6, Amy Trentham-Dietz2,3.   

Abstract

OBJECTIVE: Breast cancer simulation models must take changing mortality rates into account to evaluate the potential impact of cancer control interventions. We estimated mortality rates due to breast cancer and all other causes combined to determine their impact on overall mortality by year, age, and birth cohort.
METHODS: Based on mortality rates from publicly available datasets, an age-period-cohort model was used to estimate the proportion of deaths due to breast cancer for US women aged 0 to 119 years, with birth years 1900 to 2000. Breast cancer mortality was calculated as all-cause mortality multiplied by the proportion of deaths due to breast cancer; other-cause mortality was the difference between all-cause and breast cancer mortality.
RESULTS: Breast cancer and other-cause mortality rates were higher for older ages and birth cohorts. The percent of deaths due to breast cancer increased across birth cohorts from 1900 to 1940 then decreased. Among 50-year-old women, in the 1920 birth cohort, 52 (9.9%) of 100,000 deaths (95% CI, 9.8% to 10.1%) were attributed to breast cancer whereas 476 of 100,000 were due to other causes; in the 1960 birth cohort, 22 (8.5%) of 100,000 deaths (95% CI, 8.3% to 8.7%) were attributed to breast cancer with 242 of 100,000 deaths due to other causes. The percentage of all deaths due to breast cancer was highest (4.1% to 12.9%) for women in their 40s and 50s for all birth cohorts.
CONCLUSIONS: This study offers evidence that advances in breast cancer screening and treatment have reduced breast cancer mortality for women across the age spectrum, and provides estimates of age-, year- and birth cohort-specific competing mortality rates for simulation models. Other-cause mortality estimates are important in these models because most women die from causes other than breast cancer.

Entities:  

Keywords:  age-period-cohort modeling; breast cancer; mortality; simulation modeling

Mesh:

Year:  2018        PMID: 29554467      PMCID: PMC5963706          DOI: 10.1177/0272989X17717981

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  18 in total

1.  Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Authors:  Jeanne S Mandelblatt; Natasha K Stout; Clyde B Schechter; Jeroen J van den Broek; Diana L Miglioretti; Martin Krapcho; Amy Trentham-Dietz; Diego Munoz; Sandra J Lee; Donald A Berry; Nicolien T van Ravesteyn; Oguzhan Alagoz; Karla Kerlikowske; Anna N A Tosteson; Aimee M Near; Amanda Hoeffken; Yaojen Chang; Eveline A Heijnsdijk; Gary Chisholm; Xuelin Huang; Hui Huang; Mehmet Ali Ergun; Ronald Gangnon; Brian L Sprague; Sylvia Plevritis; Eric Feuer; Harry J de Koning; Kathleen A Cronin
Journal:  Ann Intern Med       Date:  2016-01-12       Impact factor: 25.391

2.  Age-period-cohort models for the Lexis diagram.

Authors:  B Carstensen
Journal:  Stat Med       Date:  2007-07-10       Impact factor: 2.373

3.  Breast cancer statistics, 2015: Convergence of incidence rates between black and white women.

Authors:  Carol E DeSantis; Stacey A Fedewa; Ann Goding Sauer; Joan L Kramer; Robert A Smith; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-10-29       Impact factor: 508.702

4.  Health-related lifestyle factors and mammography screening attendance in a Swedish cohort study.

Authors:  Magdalena Lagerlund; Isabel Drake; Elisabet Wirfält; Jessica M Sontrop; Sophia Zackrisson
Journal:  Eur J Cancer Prev       Date:  2015-01       Impact factor: 2.497

5.  Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.

Authors:  Ismail Jatoi; Bingshu E Chen; William F Anderson; Philip S Rosenberg
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

6.  The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: Results and reflections.

Authors:  Tim Byers; Richard C Wender; Ahmedin Jemal; Arnold M Baskies; Elizabeth E Ward; Otis W Brawley
Journal:  CA Cancer J Clin       Date:  2016-05-13       Impact factor: 508.702

7.  Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.

Authors:  Brian L Sprague; Natasha K Stout; Clyde Schechter; Nicolien T van Ravesteyn; Mucahit Cevik; Oguzhan Alagoz; Christoph I Lee; Jeroen J van den Broek; Diana L Miglioretti; Jeanne S Mandelblatt; Harry J de Koning; Karla Kerlikowske; Constance D Lehman; Anna N A Tosteson
Journal:  Ann Intern Med       Date:  2015-02-03       Impact factor: 25.391

8.  Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect.

Authors:  M Alan Brookhart; Amanda R Patrick; Colin Dormuth; Jerry Avorn; William Shrank; Suzanne M Cadarette; Daniel H Solomon
Journal:  Am J Epidemiol       Date:  2007-05-15       Impact factor: 4.897

9.  Derivation of background mortality by smoking and obesity in cancer simulation models.

Authors:  Y Claire Wang; Barry I Graubard; Marjorie A Rosenberg; Karen M Kuntz; Ann G Zauber; Lisa Kahle; Clyde B Schechter; Eric J Feuer
Journal:  Med Decis Making       Date:  2012-11-06       Impact factor: 2.583

10.  Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention.

Authors:  Jeanne Mandelblatt; Nicolien van Ravesteyn; Clyde Schechter; Yaojen Chang; An-Tsun Huang; Aimee M Near; Harry de Koning; Ahmedin Jemal
Journal:  Cancer       Date:  2013-04-26       Impact factor: 6.860

View more
  13 in total

1.  Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Authors:  Sylvia K Plevritis; Diego Munoz; Allison W Kurian; Natasha K Stout; Oguzhan Alagoz; Aimee M Near; Sandra J Lee; Jeroen J van den Broek; Xuelin Huang; Clyde B Schechter; Brian L Sprague; Juhee Song; Harry J de Koning; Amy Trentham-Dietz; Nicolien T van Ravesteyn; Ronald Gangnon; Young Chandler; Yisheng Li; Cong Xu; Mehmet Ali Ergun; Hui Huang; Donald A Berry; Jeanne S Mandelblatt
Journal:  JAMA       Date:  2018-01-09       Impact factor: 56.272

2.  Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.

Authors:  Amy Trentham-Dietz; Mehmet Ali Ergun; Oguzhan Alagoz; Natasha K Stout; Ronald E Gangnon; John M Hampton; Kim Dittus; Ted A James; Pamela M Vacek; Sally D Herschorn; Elizabeth S Burnside; Anna N A Tosteson; Donald L Weaver; Brian L Sprague
Journal:  Breast Cancer Res Treat       Date:  2017-11-28       Impact factor: 4.872

3.  Cost Effectiveness of Gene Expression Profile Testing in Community Practice.

Authors:  Young Chandler; Clyde B Schechter; Jinani Jayasekera; Aimee Near; Suzanne C O'Neill; Claudine Isaacs; Charles E Phelps; G Thomas Ray; Tracy A Lieu; Scott Ramsey; Jeanne S Mandelblatt
Journal:  J Clin Oncol       Date:  2018-01-08       Impact factor: 44.544

4.  Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study.

Authors:  Jennifer M Yeh; Kathryn P Lowry; Clyde B Schechter; Lisa R Diller; Oguzhan Alagoz; Gregory T Armstrong; John M Hampton; Wendy Leisenring; Qi Liu; Jeanne S Mandelblatt; Diana L Miglioretti; Chaya S Moskowitz; Kevin C Oeffinger; Amy Trentham-Dietz; Natasha K Stout
Journal:  Ann Intern Med       Date:  2020-07-07       Impact factor: 25.391

5.  Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.

Authors:  Kathryn P Lowry; H Amarens Geuzinge; Natasha K Stout; Oguzhan Alagoz; John Hampton; Karla Kerlikowske; Harry J de Koning; Diana L Miglioretti; Nicolien T van Ravesteyn; Clyde Schechter; Brian L Sprague; Anna N A Tosteson; Amy Trentham-Dietz; Donald Weaver; Martin J Yaffe; Jennifer M Yeh; Fergus J Couch; Chunling Hu; Peter Kraft; Eric C Polley; Jeanne S Mandelblatt; Allison W Kurian; Mark E Robson
Journal:  JAMA Oncol       Date:  2022-04-01       Impact factor: 33.006

6.  Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort.

Authors:  Marc D Ryser; Jane Lange; Lurdes Y T Inoue; Ellen S O'Meara; Charlotte Gard; Diana L Miglioretti; Jean-Luc Bulliard; Andrew F Brouwer; E Shelley Hwang; Ruth B Etzioni
Journal:  Ann Intern Med       Date:  2022-03-01       Impact factor: 51.598

7.  Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.

Authors:  Oguzhan Alagoz; Donald A Berry; Harry J de Koning; Eric J Feuer; Sandra J Lee; Sylvia K Plevritis; Clyde B Schechter; Natasha K Stout; Amy Trentham-Dietz; Jeanne S Mandelblatt
Journal:  Med Decis Making       Date:  2018-04       Impact factor: 2.583

8.  Long-Term Outcomes and Cost-Effectiveness of Breast Cancer Screening With Digital Breast Tomosynthesis in the United States.

Authors:  Kathryn P Lowry; Amy Trentham-Dietz; Clyde B Schechter; Oguzhan Alagoz; William E Barlow; Elizabeth S Burnside; Emily F Conant; John M Hampton; Hui Huang; Karla Kerlikowske; Sandra J Lee; Diana L Miglioretti; Brian L Sprague; Anna N A Tosteson; Martin J Yaffe; Natasha K Stout
Journal:  J Natl Cancer Inst       Date:  2020-06-01       Impact factor: 13.506

Review 9.  Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts.

Authors:  Amy Trentham-Dietz; Oguzhan Alagoz; Christina Chapman; Xuelin Huang; Jinani Jayasekera; Nicolien T van Ravesteyn; Sandra J Lee; Clyde B Schechter; Jennifer M Yeh; Sylvia K Plevritis; Jeanne S Mandelblatt
Journal:  PLoS Comput Biol       Date:  2021-06-17       Impact factor: 4.475

10.  Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness.

Authors:  Jennifer M Yeh; Kathryn P Lowry; Clyde B Schechter; Lisa R Diller; Grace O'Brien; Oguzhan Alagoz; Gregory T Armstrong; John M Hampton; Melissa M Hudson; Wendy Leisenring; Qi Liu; Jeanne S Mandelblatt; Diana L Miglioretti; Chaya S Moskowitz; Paul C Nathan; Joseph P Neglia; Kevin C Oeffinger; Amy Trentham-Dietz; Natasha K Stout
Journal:  J Natl Cancer Inst       Date:  2022-02-07       Impact factor: 11.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.